Enspire DBS Therapy raises $10.3M Series B1 for stroke rehabilitation neurostimulation
Summary
Enspire DBS Therapy raised $10.3 million in Series B1 financing led by Genesys Capital, with participation from existing investors Cleveland Clinic and JobsOhio Ventures. The Cleveland, Ohio-based company is developing an implantable deep brain stimulation system combined with structured rehabilitation to restore upper-extremity motor function in chronic stroke survivors. Proceeds will advance patient enrollment in the RESTORE pivotal clinical trial.
Why it matters
Enspire represents a pioneering approach to stroke rehabilitation by combining DBS with physical therapy to reactivate neural plasticity in chronic stroke patients who have plateaued in recovery. Published results from the EDEN trial in Nature Medicine demonstrated meaningful motor improvements, and the RESTORE pivotal trial could establish the first FDA-approved DBS therapy specifically for stroke rehabilitation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial